Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Adyen N.V.'s stock rebounds with strong H2 2024 results and growth in North America. Click here to find out why ADYEY is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback